Patents by Inventor Niels Lindner

Niels Lindner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230141809
    Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 9, 2022
    Publication date: May 11, 2023
    Inventors: Walter HUEBSCH, Nils GRIEBENOW, Hans-Georg SCHWARZ, Daniel KULKE, Claudia BOEHM, Kirsten BOERNGEN, Bernd ALIG, Wei ZHUANG, Iring HEISLER, Thomas ILG, Johannes KOEBBERLING, Adeline KOEHLER, Niels LINDNER, Ulrich GOERGENS, Claudia WELZ, Maike HINK
  • Publication number: 20230115270
    Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
  • Publication number: 20230065629
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
  • Patent number: 11572357
    Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: February 7, 2023
    Assignee: Bayer Animal Health GmbH
    Inventors: Walter Hübsch, Nils Griebenow, Hans-Georg Schwarz, Daniel Kulke, Claudia Böhm, Kirsten Börngen, Bernd Alig, Wei Zhuang, Iring Heisler, Thomas Ilg, Johannes Köbberling, Adeline Köhler, Niels Lindner, Ulrich Görgens, Claudia Welz, Maike Hink
  • Publication number: 20230027985
    Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 26, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
  • Patent number: 11505545
    Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: November 22, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Walter Hübsch, Johannes Köbberling, Adeline Köhler, Hans-Georg Schwarz, Daniel Kulke, Claudia Welz, Thomas Ilg, Kirsten Börngen, Wei Zhuang, Nils Griebnow, Claudia Böhm, Niels Lindner, Maike Hink, Ulrich Görgens
  • Publication number: 20220324865
    Abstract: The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 13, 2022
    Inventors: Steffen MUELLER, Rudolf SCHOHE-LOOP, Nuria ORTEGA HERNANDEZ, Frank SUESSMEIER, Eloisa JIMENEZ NUNEZ, Thomas BRUMBY, Niels LINDNER, Christoph GERDES, Elisabeth POOK, Anja BUCHMUELLER, Fabienne Zdenka GAUGAZ, Dieter LANG, Stefanie ZIMMERMANN, Alexander Helmut Michael EHRMANN, Michael GERISCH, Lutz LEHMANN, Andreas TIMMERMANN, Martina SCHAEFER, Georg SCHMIDT, Karl-Heinz SCHLEMMER, Markus FOLLMANN, Elisabeth KERSTEN, Vivian WANG, Xiang GAO, Yafeng WANG
  • Publication number: 20220259228
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Udo Albus, Doris Gehring, Björn Rosenstein, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter
  • Publication number: 20220017540
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
  • Patent number: 11208400
    Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 28, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
  • Patent number: 11173151
    Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: November 16, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Hanna Tinel, Niels Lindner, Heiko Schirmer
  • Patent number: 11098063
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: August 24, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein
  • Publication number: 20210139468
    Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 7, 2019
    Publication date: May 13, 2021
    Inventors: Walter HÜBSCH, Nils GRIEBENOW, Hans-Georg SCHWARZ, Daniel KULKE, Claudia BÖHM, Kirsten BÖRNGEN, Bernd ALIG, Wei ZHUANG, Iring HEISLER, Thomas ILG, Johannes KÖBBERLING, Adeline KÖHLER, Niels LINDNER, Ulrich GÖRGENS, Claudia WELZ, Maike HINK
  • Publication number: 20210115026
    Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 22, 2021
    Inventors: Walter HÜBSCH, Johannes KÖBBERLING, Adeline KÖHLER, Hans-Georg SCHWARZ, Daniel KULKE, Claudia WELZ, Thomas ILG, Kirsten BÖRNGEN, Wei ZHUANG, Nils GRIEBNOW, Claudia BÖHM, Niels LINDNER, Maike HINK, Ulrich GÖRGENS
  • Publication number: 20210024545
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1-and/or TASK-3-blocking properties.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 28, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Johanna ANLAHR, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER
  • Patent number: 10889573
    Abstract: The present invention covers new quinoline compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 12, 2021
    Assignee: Bayer Animal Health GMBH
    Inventors: Walter Hübsch, Johannes Köbberling, Adeline Köhler, Hans-Georg Schwarz, Daniel Kulke, Claudia Welz, Thomas Ilg, Kirsten Börngen, Wei Zhuang, Nils Griebenow, Claudia Böhm, Niels Lindner, Maike Hink, Ulrich Görgens
  • Publication number: 20200316045
    Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Application
    Filed: October 17, 2018
    Publication date: October 8, 2020
    Inventors: Marie-Pierre COLLIN-KROEPELIN, Peter KOLKHOF, Thomas NEUBAUER, Chantal FUERSTNER, Elisabeth POOK, Matthias Beat WITTWER, Klemens LUSTIG, Hanna TINEL, Niels LINDNER, Heiko SCHIRMER
  • Patent number: 10722501
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 28, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
  • Patent number: 10662185
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 26, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Markus Follman, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haßfeld, Niels Lindner, Alexey Gromov, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Andreas Knorr
  • Publication number: 20200109155
    Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 9, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN